New and more effective treatments for mental health conditions represent one of the greatest unmet demands in healthcare today.

Under the expert clinical direction of Dr. Allan S. Kaplan,  a senior clinician at the Center for Addiction and Mental Health (CAMH) in Toronto and Professor in the Department of Psychiatry at the University of Toronto’s Temerty Faculty of Medicine, Xpira Pharmaceuticals is working to address those demands by leveraging cutting-edge research from leaders in North American and Dutch pharmaceutical development.

With a particular focus on eating disorders, Xpira is dedicated to the use of psychedelic molecules in the creation of new treatment options for patients suffering from some of the most detrimental chronic mental health disorders known to psychology today.